Identification

Name
Nafamostat
Accession Number
DB12598
Type
Small Molecule
Groups
Approved, Investigational
Description

Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

Structure
Thumb
Synonyms
  • FUT-175
  • Nafamostat dimethanesulfonate
  • Nafamostat mesilate
Product Ingredients
IngredientUNIICASInChI Key
Nafamostat mesylate1D2T74921W82956-11-4ZESSXQLDESEKGC-UHFFFAOYSA-N
International/Other Brands
Berabu (Tobishi Pharmaceutical, Japan) / Buipel (Teva Seiyaku, Japan) / Buseron (Sawai Seiyaku, Japan) / Coahibitor (AY Pharma, Japan) / Famoset (Towa Yakuhin, Japan) / Futhan (Torii Yakuhin, Japan) / Nafaston (Fuji Seiyaku, Japan) / Nafatat (Nichi-Iko Pharmaceutical, Japan) / Namostatt (Pola Pharma, Japan) / Naotamin (Asahi Kasei Pharma, Japan) / Opsun (Sanwa Kagaku, Japan) / Pathron (Nipro, Japan) / Ronastat (Koa Isei, Japan)
Categories
UNII
Y25LQ0H97D
CAS number
81525-10-2
Weight
Average: 347.378
Monoisotopic: 347.138224807
Chemical Formula
C19H17N5O2
InChI Key
MQQNFDZXWVTQEH-UHFFFAOYSA-N
InChI
InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
IUPAC Name
6-carbamimidoylnaphthalen-2-yl 4-carbamimidamidobenzoate
SMILES
NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N

Pharmacology

Indication

Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.

Pharmacodynamics

Nafamostat is a fast-acting proteolytic inhibitor used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin by competitively inhibiting several serine proteases including thrombin. It improves acute pancreatitis and prevents blood clot formation during extracorporeal circulation and has an anti-inflammatory effect in vitro. A study suggets that nafamostat has a neuroprotective role during ischemia-induced brain injury from antithrombin activity [5].

Mechanism of action

Nafamostat mesilate inhibits various enzyme systems, such as coagulation and fibrinolytic systems (thrombin, Xa, and XIIa), the kallikrein–kinin system, the complement system, pancreatic proteases and activation of protease-activated receptors (PARs) [6]. Nafamostat inhibits lipopolysaccharide-induced nitric oxide production, apoptosis, and interleukin (IL)-6 and IL-8 levels in cultured human trophoblasts. It is shown to act as an antioxidant in TNF-α-induced ROS production [2].

TargetActionsOrganism
AProthrombin
inhibitor
Human
ACoagulation factor X
inhibitor
Human
ACoagulation factor XII
inhibitor
Human
ATrypsin-1
inhibitor
Human
AKallikrein-1
inhibitor
Human
UIntercellular adhesion molecule 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Nafamostat is mainly hydrolyzed by hepatic carboxyesterase and long-chain acyl-CoA hydrolase in human liver cytosol. Main metabolites are p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN) as inactive protease inhibitors.

Route of elimination

Two metabolites of NM, p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN), are renally excreted. Nafamostat accumulates in the kidneys.

Half life

Approximately 8 minutes [4]

Clearance
Not Available
Toxicity

Reported incidences of agranulocytosis, hyperkalemia, and anaphylaxis. The use of nafamostat has been reported to cause cardiac arrest in patients receiving dialysis due to a sudden change in the patient's condition such as dyspnea. A study suggests that the drug and its metabolites may inhibit the amiloride-sensitive sodium (Na) conductance at the collecting ducts, resulting in an inhibition of K secretion and hyperkalemia [7]. Reported LD50 value from intravenous administration in rats is 16.4mg/kg.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Nafamostat.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 5-androstenedione.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Nafamostat.Approved, Investigational
AbciximabNafamostat may increase the anticoagulant activities of Abciximab.Approved
AcebutololNafamostat may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNafamostat may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Nafamostat.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Alendronic acid.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Nafamostat.Approved, Investigational
AliskirenNafamostat may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Nafamostat.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Nafamostat.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Nafamostat.Approved, Illicit, Investigational
AlprenololNafamostat may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nafamostat.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Nafamostat.Approved
AltrenogestThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Altrenogest.Vet Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nafamostat.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Amcinonide.Approved
AmikacinNafamostat may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideNafamostat may decrease the antihypertensive activities of Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Nafamostat.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Nafamostat.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Aminosalicylic Acid.Approved
AmiodaroneNafamostat may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nafamostat.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Nafamostat.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Nafamostat.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Nafamostat.Approved
AncrodNafamostat may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Nafamostat.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Nafamostat is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Nafamostat is combined with anecortave acetate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Nafamostat.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Nafamostat.Approved
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Nafamostat is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Antipyrine.Approved, Investigational
Antithrombin III humanNafamostat may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Antrafenine.Approved
ApixabanApixaban may increase the anticoagulant activities of Nafamostat.Approved
ApocyninApocynin may increase the anticoagulant activities of Nafamostat.Investigational
ApramycinNafamostat may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
ArbekacinNafamostat may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNafamostat may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNafamostat may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNafamostat may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineNafamostat may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinAstaxanthin may increase the anticoagulant activities of Nafamostat.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Atamestane.Investigational
AtenololNafamostat may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Nafamostat.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Nafamostat.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Nafamostat is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nafamostat.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nafamostat.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Balsalazide.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Nafamostat.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Nafamostat.Investigational
BecaplerminNafamostat may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNafamostat may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNafamostat may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinBemiparin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Benazepril.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Nafamostat.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nafamostat.Approved
BenorilateBenorilate may increase the anticoagulant activities of Nafamostat.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Nafamostat.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nafamostat.Approved
BenzydamineBenzydamine may increase the anticoagulant activities of Nafamostat.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nafamostat.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Betamethasone.Approved, Vet Approved
BetaxololNafamostat may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Nafamostat.Approved, Investigational
BevantololNafamostat may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumBevonium may increase the anticoagulant activities of Nafamostat.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nafamostat.Approved, Investigational
BisoprololNafamostat may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNafamostat may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Nafamostat can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BopindololNafamostat may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseBrinase may increase the anticoagulant activities of Nafamostat.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nafamostat.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Nafamostat.Investigational
BucindololNafamostat may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Bufexamac.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Nafamostat.Experimental
BufuralolNafamostat may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneBumadizone may increase the anticoagulant activities of Nafamostat.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nafamostat.Approved
BupranololNafamostat may decrease the antihypertensive activities of Bupranolol.Approved
BupropionThe serum concentration of Nafamostat can be increased when it is combined with Bupropion.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Nafamostat.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Nafamostat.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Nafamostat.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nafamostat.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nafamostat.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Nafamostat.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Nafamostat.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Captopril.Approved
CarbamazepineThe metabolism of Nafamostat can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Nafamostat.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nafamostat.Approved
CarprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNafamostat may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNafamostat may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the anticoagulant activities of Nafamostat.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Celecoxib.Approved, Investigational
CeliprololNafamostat may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNafamostat may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlormadinoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Chlormadinone.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Nafamostat.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nafamostat.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cimicoxib.Investigational
CinoxacinNafamostat may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinNafamostat may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cisplatin.Approved
Citric AcidNafamostat may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nafamostat.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Nafamostat.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Nafamostat.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Nafamostat.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nafamostat.Vet Approved
CloranololNafamostat may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenCloricromen may increase the anticoagulant activities of Nafamostat.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Nafamostat.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Nafamostat is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ColesevelamColesevelam can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Nafamostat is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Nafamostat.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Nafamostat is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CurcuminCurcumin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nafamostat.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nafamostat.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Nafamostat.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Nafamostat.Experimental
DalteparinNafamostat may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNafamostat may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNafamostat may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Nafamostat.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Nafamostat.Approved
DemegestoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Demegestone.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Nafamostat.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Nafamostat.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Nafamostat.Approved, Investigational
DesirudinNafamostat may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Nafamostat.Investigational
DesogestrelThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Desogestrel.Approved
DesonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nafamostat.Approved, Investigational
DextranNafamostat may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinNafamostat may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Nafamostat.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nafamostat.Approved, Vet Approved
DicoumarolNafamostat may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
DienogestThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nafamostat.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Nafamostat.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Nafamostat is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nafamostat.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Nafamostat.Approved, Investigational
DihydrostreptomycinNafamostat may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Nafamostat.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Nafamostat.Approved, Withdrawn
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nafamostat.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nafamostat.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nafamostat.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Nafamostat.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Nafamostat.Approved
DitazoleDitazole may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Nafamostat.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Nafamostat.Approved, Investigational
DrospirenoneNafamostat may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Nafamostat is combined with Droxicam.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Nafamostat.Investigational
DydrogesteroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Nafamostat.Approved
E-6201E-6201 may increase the anticoagulant activities of Nafamostat.Investigational
Edetic AcidNafamostat may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Nafamostat.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Nafamostat.Approved, Investigational
EnoxacinNafamostat may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNafamostat may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Nafamostat.Experimental
EpanololNafamostat may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolEpimestrol may decrease the anticoagulant activities of Nafamostat.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Nafamostat.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nafamostat.Experimental
EplerenoneNafamostat may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Nafamostat.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Nafamostat.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nafamostat.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nafamostat.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Nafamostat is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Equilin.Approved
EquolEquol may decrease the anticoagulant activities of Nafamostat.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nafamostat.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Nafamostat.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Nafamostat.Approved
EsatenololNafamostat may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololNafamostat may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Nafamostat.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Nafamostat.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Nafamostat.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Nafamostat.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Nafamostat.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Nafamostat.Approved
EstroneEstrone may decrease the anticoagulant activities of Nafamostat.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nafamostat.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etanercept.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Nafamostat.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nafamostat.Approved
Ethyl biscoumacetateNafamostat may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Ethynodiol.Experimental
Etidronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Nafamostat.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Nafamostat.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Nafamostat.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Nafamostat.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Nafamostat.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nafamostat.Vet Approved
FentiazacFentiazac may increase the anticoagulant activities of Nafamostat.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Nafamostat.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Nafamostat.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Nafamostat.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nafamostat.Approved, Investigational
FingolimodNafamostat may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fish oil.Approved, Nutraceutical
FleroxacinNafamostat may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nafamostat.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fludrocortisone.Approved, Investigational
FluindioneNafamostat may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineNafamostat may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Nafamostat.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Nafamostat.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nafamostat.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nafamostat.Approved, Nutraceutical, Vet Approved
FondaparinuxNafamostat may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nafamostat.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fosinopril.Approved
FramycetinNafamostat may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Nafamostat is combined with G17DT.Investigational
GabexateNafamostat may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNafamostat may increase the neuroexcitatory activities of Garenoxacin.Investigational
GarlicThe serum concentration of Nafamostat can be decreased when it is combined with Garlic.Approved, Nutraceutical
GatifloxacinNafamostat may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nafamostat.Approved, Withdrawn
GemifloxacinNafamostat may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNafamostat may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinGenistein may decrease the anticoagulant activities of Nafamostat.Investigational
GentamicinNafamostat may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANafamostat may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestrinone.Approved
GI-5005The risk or severity of adverse effects can be increased when Nafamostat is combined with GI-5005.Investigational
GinsengThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinNafamostat may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the anticoagulant activities of Nafamostat.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Nafamostat is combined with HE3286.Investigational
HeminHemin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Nafamostat.Experimental
HeparinNafamostat may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Nafamostat is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolHexestrol may decrease the anticoagulant activities of Nafamostat.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Nafamostat.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Human rabies virus immune globulin.Approved
HydralazineNafamostat may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Nafamostat.Investigational
Hygromycin BNafamostat may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nafamostat.Approved
IbudilastIbudilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibuprofen.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Nafamostat.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Nafamostat.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Nafamostat is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Nutraceutical
IdraparinuxNafamostat may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Nafamostat.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nafamostat.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Imidapril.Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Nafamostat.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nafamostat.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nafamostat.Approved
IndenololNafamostat may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenIndobufen may increase the anticoagulant activities of Nafamostat.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Nafamostat.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 225.Investigational
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Nafamostat.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nafamostat.Approved, Investigational
IsavuconazoleThe serum concentration of Nafamostat can be increased when it is combined with Isavuconazole.Approved, Investigational
IsepamicinNafamostat may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamIsoxicam may increase the anticoagulant activities of Nafamostat.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nafamostat is combined with Istaroxime.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Nafamostat is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinNafamostat may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneKebuzone may increase the anticoagulant activities of Nafamostat.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Nafamostat.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nafamostat.Approved
LabetalolNafamostat may decrease the antihypertensive activities of Labetalol.Approved
LandiololNafamostat may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nafamostat.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nafamostat.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Leflunomide.Approved, Investigational
LepirudinNafamostat may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNafamostat may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololNafamostat may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololNafamostat may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNafamostat may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Nafamostat.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Nafamostat.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Nafamostat.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Nafamostat.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Nafamostat.Experimental
LomefloxacinNafamostat may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacLonazolac may increase the anticoagulant activities of Nafamostat.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Nafamostat is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nafamostat.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nafamostat.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nafamostat.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nafamostat.Vet Approved
LynestrenolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Lynestrenol.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Magnesium salicylate.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Nafamostat is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Meclofenamic acid.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Mefenamic acid.Approved
Megestrol acetateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranNafamostat may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Melengestrol.Vet Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Nafamostat.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Nafamostat is combined with Meloxicam.Approved, Vet Approved
MepindololNafamostat may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Nafamostat.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Nafamostat.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nafamostat.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nafamostat.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Nafamostat.Approved
MethylestrenoloneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Methylestrenolone.Experimental
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNafamostat may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat.Approved
MetoprololNafamostat may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinNafamostat may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nafamostat.Approved, Illicit
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nafamostat.Approved, Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Nafamostat.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nafamostat.Approved
MizoribineMizoribine may increase the anticoagulant activities of Nafamostat.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Moexipril.Approved
MofebutazoneMofebutazone may increase the anticoagulant activities of Nafamostat.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nafamostat.Approved
MoxestrolMoxestrol may decrease the anticoagulant activities of Nafamostat.Experimental
MoxifloxacinNafamostat may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Nafamostat.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nabumetone.Approved
NadololNafamostat may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNafamostat may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Nafamostat.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Nafamostat.Investigational
Nalidixic AcidNafamostat may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Nafamostat is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Nafamostat is combined with NCX 1022.Investigational
NeamineNafamostat may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNafamostat may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Nafamostat.Approved, Withdrawn
NemonoxacinNafamostat may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNafamostat may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nepafenac.Approved, Investigational
NetilmicinNafamostat may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Nafamostat.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nimesulide.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Nafamostat.Investigational
NomegestrolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNafamostat may increase the neuroexcitatory activities of Norfloxacin.Approved
NorgestrienoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Nafamostat.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nafamostat is combined with Obinutuzumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Nafamostat.Approved, Investigational
OfloxacinNafamostat may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nafamostat.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Nafamostat.Approved
OlsalazineNafamostat may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Nafamostat is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Nafamostat.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Nafamostat can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Nafamostat.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Nafamostat.Vet Approved
OtamixabanNafamostat may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Oxaprozin.Approved
Oxolinic acidNafamostat may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNafamostat may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Nafamostat.Investigational
PalmidrolPalmidrol may increase the anticoagulant activities of Nafamostat.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Parecoxib.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
ParomomycinNafamostat may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
PazufloxacinNafamostat may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNafamostat may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNafamostat may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNafamostat may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Nafamostat.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Nafamostat.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pethidine.Approved
PhenindioneNafamostat may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNafamostat may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Nafamostat.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Phenylbutazone.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Nafamostat.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nafamostat.Approved, Investigational
PindololNafamostat may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidNafamostat may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nafamostat.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Piromidic acidNafamostat may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Nafamostat is combined with Piroxicam.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Nafamostat.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorNafamostat may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNafamostat may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Nafamostat.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nafamostat.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pomalidomide.Approved
Potassium CitrateNafamostat may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololNafamostat may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nafamostat.Approved, Investigational
PranoprofenPranoprofen may increase the anticoagulant activities of Nafamostat.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prasterone sulfate.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Nafamostat.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Nafamostat can be increased when it is combined with Probenecid.Approved, Investigational
ProgesteroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Nafamostat.Experimental
PromegestoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Nafamostat.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
PropafenoneNafamostat may decrease the antihypertensive activities of Propafenone.Approved
PropranololNafamostat may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Nafamostat.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Nafamostat.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nafamostat.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nafamostat.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nafamostat.Vet Approved
Protein CNafamostat may increase the anticoagulant activities of Protein C.Approved
Protein S humanNafamostat may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNafamostat may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Nafamostat.Approved
PrulifloxacinNafamostat may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the anticoagulant activities of Nafamostat.Investigational
PuromycinNafamostat may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Nafamostat.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nafamostat.Approved
QuingestanolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Quingestanol.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nafamostat.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Nafamostat.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ramipril.Approved
RelcovaptanRelcovaptan may increase the anticoagulant activities of Nafamostat.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Nafamostat.Approved, Investigational
ReviparinNafamostat may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNafamostat may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Nafamostat.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rindopepimut.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Nafamostat.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Risedronate.Approved, Investigational
RivaroxabanNafamostat may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Nafamostat.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
RosoxacinNafamostat may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinNafamostat may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nafamostat.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Nafamostat.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Salicylic acid.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nafamostat.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nafamostat.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Nafamostat.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Nafamostat.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Nafamostat.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Nafamostat.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Nafamostat.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Seliciclib.Investigational
SemapimodSemapimod may increase the anticoagulant activities of Nafamostat.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Nafamostat.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Nafamostat.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Nafamostat.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nafamostat.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nafamostat.Approved, Investigational
SisomicinNafamostat may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNafamostat may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateNafamostat may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicSodium phosphate may increase the nephrotoxic activities of Nafamostat.Approved
SotalolNafamostat may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinNafamostat may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Spirapril.Approved
SpironolactoneNafamostat may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Nafamostat is combined with SRP 299.Investigational
SRT501SRT501 may increase the anticoagulant activities of Nafamostat.Investigational
St. John's WortThe metabolism of Nafamostat can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseStreptokinase may increase the anticoagulant activities of Nafamostat.Approved, Investigational
StreptomycinNafamostat may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SugammadexSugammadex may increase the anticoagulant activities of Nafamostat.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Sulindac.Approved, Investigational
SulodexideNafamostat may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nafamostat.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Nafamostat is combined with Suprofen.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Nafamostat.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Nafamostat.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nafamostat.Approved
TacrolimusTacrolimus may increase the immunosuppressive activities of Nafamostat.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nafamostat.Approved
TalinololNafamostat may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nafamostat.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Nafamostat.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nafamostat.Approved
TecemotideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tecemotide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nafamostat.Approved, Investigational
TemafloxacinNafamostat may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Nafamostat.Approved
TenidapTenidap may increase the anticoagulant activities of Nafamostat.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tenoxicam.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Nafamostat.Vet Approved
TerbutalineNafamostat may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Nafamostat.Approved
TertatololNafamostat may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the anticoagulant activities of Nafamostat.Investigational
Testosterone cypionateThe therapeutic efficacy of Nafamostat can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Nafamostat can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Nafamostat can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Nafamostat is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Nafamostat.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Nafamostat.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tiaprofenic acid.Approved
TiboloneTibolone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Nafamostat.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Nafamostat.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNafamostat may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the anticoagulant activities of Nafamostat.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Nafamostat.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Nafamostat.Experimental
TipiracilThe serum concentration of Tipiracil can be increased when it is combined with Nafamostat.Approved, Investigational
TipranavirThe serum concentration of Nafamostat can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Nafamostat.Approved
TixocortolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tixocortol.Approved, Withdrawn
TobramycinNafamostat may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibNafamostat may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nafamostat.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Trandolapril.Approved
TranilastTranilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Nafamostat.Approved
TrastuzumabTrastuzumab may increase the neutropenic activities of Nafamostat.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nafamostat.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nafamostat.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNafamostat may decrease the antihypertensive activities of Triamterene.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Nafamostat.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Nafamostat.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Nafamostat.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Nafamostat.Approved
TriptolideTriptolide may increase the anticoagulant activities of Nafamostat.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Trolamine salicylate.Approved
TrovafloxacinNafamostat may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNafamostat may increase the anticoagulant activities of Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nafamostat.Approved, Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Nafamostat.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nafamostat.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nafamostat.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Nafamostat is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Nafamostat.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Nafamostat.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Nafamostat.Approved
WarfarinNafamostat may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNafamostat may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Nafamostat.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Nafamostat.Approved
ZileutonZileuton may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Nafamostat.Withdrawn
Food Interactions
Not Available

References

General References
  1. Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T: Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs. 2011 Jul;34(7):571-6. doi: 10.5301/IJAO.2011.8535. [PubMed:21786254]
  2. Kang MW, Song HJ, Kang SK, Kim Y, Jung SB, Jee S, Moon JY, Suh KS, Lee SD, Jeon BH, Kim CS: Nafamostat Mesilate Inhibits TNF-alpha-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Korean J Physiol Pharmacol. 2015 May;19(3):229-34. doi: 10.4196/kjpp.2015.19.3.229. Epub 2015 Apr 30. [PubMed:25954127]
  3. Choi S, Kwon HJ, Song HJ, Choi SW, Nagar H, Piao S, Jung SB, Jeon BH, Kim DW, Kim CS: Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Korean J Physiol Pharmacol. 2016 Sep;20(5):539-45. doi: 10.4196/kjpp.2016.20.5.539. Epub 2016 Aug 26. [PubMed:27610041]
  4. Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD: Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial. Medicine (Baltimore). 2015 Dec;94(52):e2392. doi: 10.1097/MD.0000000000002392. [PubMed:26717390]
  5. Chen T, Wang J, Li C, Zhang W, Zhang L, An L, Pang T, Shi X, Liao H: Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Sci Rep. 2014 Jul 2;4:5531. doi: 10.1038/srep05531. [PubMed:24985053]
  6. Kim HS, Lee KE, Oh JH, Jung CS, Choi D, Kim Y, Jeon JS, Han DC, Noh H: Cardiac arrest caused by nafamostat mesilate. Kidney Res Clin Pract. 2016 Sep;35(3):187-9. doi: 10.1016/j.krcp.2015.10.003. Epub 2015 Nov 12. [PubMed:27668164]
  7. Muto S, Imai M, Asano Y: Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J Pharmacol. 1994 Jan;111(1):173-8. [PubMed:8012693]
  8. FDA Executive Summary [Link]
External Links
PubChem Compound
4413
PubChem Substance
347828816
ChemSpider
4260
BindingDB
50063698
ChEBI
135466
ChEMBL
CHEMBL273264
Drugs.com
Drugs.com Drug Page
Wikipedia
Nafamostat
MSDS
Download (29.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionPostreperfusion Syndrome / Transplantation, Liver1
4CompletedTreatmentAcute Kidney Injury (AKI)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0341 mg/mLALOGPS
logP1.91ALOGPS
logP2.52ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)11.32ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area138.07 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity122.12 m3·mol-1ChemAxon
Polarizability37.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as guanidinobenzoic acids and derivatives. These are aromatic compounds containing a guanidine group linked to the benzene ring of a benzoic acid (or a derivative thereof).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Guanidinobenzoic acids and derivatives
Alternative Parents
Naphthalenes / Benzoic acid esters / Benzoyl derivatives / Guanidines / Carboxylic acid esters / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboximidamides / Carboxamidines / Organopnictogen compounds
show 3 more
Substituents
Guanidinobenzoic acid or derivatives / Benzoate ester / Naphthalene / Benzoyl / Carboxylic acid ester / Guanidine / Amidine / Carboxylic acid amidine / Carboxylic acid derivative / Monocarboxylic acid or derivatives
show 11 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thrombospondin receptor activity
Specific Function
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
Gene Name
F2
Uniprot ID
P00734
Uniprot Name
Prothrombin
Molecular Weight
70036.295 Da
References
  1. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T: Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986 Jun;41(2):155-62. [PubMed:2427760]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE: The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-85. doi: 10.3109/0886022X.2011.647293. Epub 2012 Jan 17. [PubMed:22251267]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII t...
Gene Name
F12
Uniprot ID
P00748
Uniprot Name
Coagulation factor XII
Molecular Weight
67791.53 Da
References
  1. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE: The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-85. doi: 10.3109/0886022X.2011.647293. Epub 2012 Jan 17. [PubMed:22251267]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form aga...
Gene Name
PRSS1
Uniprot ID
P07477
Uniprot Name
Trypsin-1
Molecular Weight
26557.88 Da
References
  1. Ramjee MK, Henderson IM, McLoughlin SB, Padova A: The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin. Thromb Res. 2000 Jun 15;98(6):559-69. [PubMed:10899355]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name
KLK1
Uniprot ID
P06870
Uniprot Name
Kallikrein-1
Molecular Weight
28889.425 Da
References
  1. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T: Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986 Jun;41(2):155-62. [PubMed:2427760]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial api...
Gene Name
ICAM1
Uniprot ID
P05362
Uniprot Name
Intercellular adhesion molecule 1
Molecular Weight
57824.785 Da
References
  1. Kang MW, Song HJ, Kang SK, Kim Y, Jung SB, Jee S, Moon JY, Suh KS, Lee SD, Jeon BH, Kim CS: Nafamostat Mesilate Inhibits TNF-alpha-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Korean J Physiol Pharmacol. 2015 May;19(3):229-34. doi: 10.4196/kjpp.2015.19.3.229. Epub 2015 Apr 30. [PubMed:25954127]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A: Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci. 2004 Feb;93(2):262-72. [PubMed:14705184]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A: Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci. 2004 Feb;93(2):262-72. [PubMed:14705184]

Drug created on October 20, 2016 17:07 / Updated on July 02, 2018 20:58